Emmaus Life Sciences Net Income
| EMMA Stock | USD 0.01 0 6.67% |
As of the 1st of March, Emmaus Life shows the Coefficient Of Variation of 788.98, mean deviation of 2.98, and Downside Deviation of 5.89. Emmaus Life Sciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen technical drivers for Emmaus Life Sciences, which can be compared to its peers.
Emmaus Life's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Emmaus Life's valuation are provided below:Emmaus Life Sciences does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Emmaus |
Emmaus Life 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Emmaus Life's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Emmaus Life.
| 12/01/2025 |
| 03/01/2026 |
If you would invest 0.00 in Emmaus Life on December 1, 2025 and sell it all today you would earn a total of 0.00 from holding Emmaus Life Sciences or generate 0.0% return on investment in Emmaus Life over 90 days. Emmaus Life is related to or competes with Orgenesis, and Helix BioMedix. Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatm... More
Emmaus Life Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Emmaus Life's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Emmaus Life Sciences upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.89 | |||
| Information Ratio | 0.1114 | |||
| Maximum Drawdown | 44.53 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 7.69 |
Emmaus Life Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Emmaus Life's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Emmaus Life's standard deviation. In reality, there are many statistical measures that can use Emmaus Life historical prices to predict the future Emmaus Life's volatility.| Risk Adjusted Performance | 0.1057 | |||
| Jensen Alpha | 0.745 | |||
| Total Risk Alpha | 0.1207 | |||
| Sortino Ratio | 0.1105 | |||
| Treynor Ratio | (4.15) |
Emmaus Life March 1, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1057 | |||
| Market Risk Adjusted Performance | (4.14) | |||
| Mean Deviation | 2.98 | |||
| Semi Deviation | 2.73 | |||
| Downside Deviation | 5.89 | |||
| Coefficient Of Variation | 788.98 | |||
| Standard Deviation | 5.85 | |||
| Variance | 34.18 | |||
| Information Ratio | 0.1114 | |||
| Jensen Alpha | 0.745 | |||
| Total Risk Alpha | 0.1207 | |||
| Sortino Ratio | 0.1105 | |||
| Treynor Ratio | (4.15) | |||
| Maximum Drawdown | 44.53 | |||
| Value At Risk | (6.67) | |||
| Potential Upside | 7.69 | |||
| Downside Variance | 34.74 | |||
| Semi Variance | 7.43 | |||
| Expected Short fall | (7.29) | |||
| Skewness | 3.05 | |||
| Kurtosis | 15.47 |
Emmaus Life Sciences Backtested Returns
Emmaus Life appears to be out of control, given 3 months investment horizon. Emmaus Life Sciences secures Sharpe Ratio (or Efficiency) of 0.12, which denotes the company had a 0.12 % return per unit of risk over the last 3 months. By reviewing Emmaus Life's technical indicators, you can evaluate if the expected return of 0.73% is justified by implied risk. Please utilize Emmaus Life's Coefficient Of Variation of 788.98, mean deviation of 2.98, and Downside Deviation of 5.89 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Emmaus Life holds a performance score of 9. The firm shows a Beta (market volatility) of -0.18, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Emmaus Life are expected to decrease at a much lower rate. During the bear market, Emmaus Life is likely to outperform the market. Please check Emmaus Life's total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Emmaus Life's price patterns will revert.
Auto-correlation | 0.11 |
Insignificant predictability
Emmaus Life Sciences has insignificant predictability. Overlapping area represents the amount of predictability between Emmaus Life time series from 1st of December 2025 to 15th of January 2026 and 15th of January 2026 to 1st of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Emmaus Life Sciences price movement. The serial correlation of 0.11 indicates that less than 11.0% of current Emmaus Life price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.11 | |
| Spearman Rank Test | 0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Emmaus Life Sciences reported net income of (15.95 Million). This is 104.67% lower than that of the Pharmaceuticals sector and 122.77% lower than that of the Health Care industry. The net income for all United States stocks is 102.79% higher than that of the company.
Emmaus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emmaus Life's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Emmaus Life could also be used in its relative valuation, which is a method of valuing Emmaus Life by comparing valuation metrics of similar companies.Emmaus Life is currently under evaluation in net income category among its peers.
Emmaus Fundamentals
| Return On Asset | -0.12 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (0.65) % | |||
| Current Valuation | 49.41 M | |||
| Shares Outstanding | 49.56 M | |||
| Shares Owned By Insiders | 38.73 % | |||
| Number Of Shares Shorted | 41.22 K | |||
| Price To Earning | (1.60) X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 20.61 M | |||
| Gross Profit | 17.3 M | |||
| EBITDA | (12.76 M) | |||
| Net Income | (15.95 M) | |||
| Cash And Equivalents | 982 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 4.65 M | |||
| Debt To Equity | (0.04) % | |||
| Current Ratio | 0.14 X | |||
| Book Value Per Share | (0.76) X | |||
| Cash Flow From Operations | (1.25 M) | |||
| Short Ratio | 0.48 X | |||
| Earnings Per Share | (0.18) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 58 | |||
| Beta | 1.97 | |||
| Market Capitalization | 24.28 M | |||
| Total Asset | 56.73 M | |||
| Retained Earnings | (82.78 M) | |||
| Working Capital | 1.95 M | |||
| Current Asset | 9.19 M | |||
| Current Liabilities | 7.25 M | |||
| Z Score | 1.6 | |||
| Net Asset | 56.73 M |
About Emmaus Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emmaus Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emmaus Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emmaus Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Emmaus OTC Stock
Emmaus Life financial ratios help investors to determine whether Emmaus OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Emmaus with respect to the benefits of owning Emmaus Life security.